drugset / Trial / NCT05502393
A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors
NaSequentialOpen-labelTreatment
Summary
The purpose of this phase I clinical study was to evaluate the safety and tolerability of JS107 monotherapy and combination with Toripalimab in patients with Advanced or Metastatic Solid Tumors.
Timeline
- Start
- 2022-07-26
- Primary completion
- 2024-07-31
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JS107 | Unknown | — | Intravenous |
| Subject | Toripalimab | Monoclonal antibody | — | Intravenous |